Corona Remedies IPO GMP Today: ₹300+ Gain?

positionalcalls.com

9 hours ago

Table of Contents

Corona Remedies IPO 2025: Snapshot

Corona Remedies Ltd is a Gujarat-based pharmaceutical company focused on branded formulations, chronic therapies, and prescription-driven products in India. The IPO is a pure OFS of about 61.7 lakh shares, aggregating to ₹655.37 crore, with no fresh issue component.

Key IPO details for quick reference:

Parameter	Details
IPO type	Mainboard, 100% Offer for sale.
Issue size	₹655.37 crore (approx. 61.7 lakh shares)
Price band	₹1,008–₹1,062 per share
Face value	₹10 per share
Bid/issue period	8 December 2025–10 December 2025
Lot size	14 shares per lot
Minimum retail investment	Around ₹14,112–₹14,868 (depending on cut-off price)
Allotment date (tentative)	11 December 2025.
Listing date (tentative)	15 December 2025, on NSE & BSE

Corona Remedies IPO: Why Corona Remedies IPO Is Trending

Corona Remedies IPO is trending among investors due to its strong profit growth, high return ratios, and active grey market premium (GMP). The company reported total income of about ₹1,202 crore in FY 2024–25, up roughly 18% year-on-year, while profit after tax (PAT) surged by around 65% to ₹149.43 crore.

Key reasons for buzz:

The company experienced double-digit revenue growth, accompanied by faster profit expansion.
The company achieved a strong return on capital employed (ROCE) of about 41% in FY25, indicating highly efficient capital usage.
Over the past few years, the company has maintained healthy EBITDA margins of approximately 20–21%.

Corona Remedies IPO: Dates, Price Band, and Lot Size

Understanding the timeline and investment amounts is crucial for high-intent IPO investors.

Corona Remedies IPO date:
8–10 December 2025
Corona Remedies IPO price band:
₹1,008–₹1,062 per equity share
Corona Remedies IPO lot size:
14 shares per lot.

Approximate investment requirements for different categories:

Retail (1 lot):
about ₹14,112–₹14,868
Retail (max 13 lots):
around ₹1.8–₹1.9 lakh
Small HNI (S-HNI, 14 lots):
about ₹2.0–₹2.1 lakh
Big HNI (bNII, 68 lots):
about ₹10 lakh+

Corona Remedies IPO GMP Today: IPO GMP and expectations for listing gains are discussed.

Several market trackers report a strong grey market premium (GMP) in the ₹300+ range over the upper price band, indicating robust listing expectations. A high and stable Corona Remedies IPO GMP generally suggests strong demand and potential listing gains, though it is unofficial and highly volatile.

Actionable tips for using GMP data:

Track the Corona Remedies IPO GMP trend for 3–4 days before the issue opening.
Focus on direction (rising or falling) rather than absolute GMP alone.
Avoid over-leveraging solely based on grey market signals; combine with fundamentals.

Company Overview and Business Model

Corona Remedies mainly focuses on branded generic and specialty pharmaceutical products, particularly in areas like heart health, diabetes, and other lifestyle-related treatments. The company distributes largely through doctors’ prescriptions, field-force marketing, and a strong pan-India network.

Business strengths that appeal to IPO investors:

The company’s diversified product portfolio, which includes both chronic and sub-chronic therapies, typically ensures more stable and recurring demand.
The company has expanded its reach into metros and Tier-II/III cities, thereby mitigating the risk of geographic concentration.
Focus on branded play rather than pure commodity generics, allowing relatively better margins.

Financial Performance: Revenue, Profit, Margins, and ROCE

Strong financials are a core reason many investors are searching for the Corona Remedies IPO review and Corona Remedies IPO fundamentals.

Key recent financials (₹ crore):

FY23 total income:
about ₹891 crore; PAT: ~₹84.9 crore
FY24 total income:
about ₹1,021 crore; PAT: ~₹90.5 crore
FY25 total income:
about ₹1,202 crore; PAT: ~₹149.4 crore

Quality metrics:

EBITDA margin:
around 20–21% recently.
ROCE:
The projected ROCE is around 41% in FY25, which places the company among high-ROCE pharma players.
The company’s net worth exceeds ₹600 crore, and its moderate borrowings indicate a comfortable balance sheet.

For investors screening IPOs using fundamentals, Corona Remedies scores well on growth, profitability, and capital efficiency.

Key Risks in Corona Remedies IPO

Even with attractive metrics, a balanced Corona Remedies IPO analysis must consider risks.

Main risk factors:

Regulatory risk:
Pharma is tightly regulated; any compliance issues with Indian or overseas regulators could impact operations.
Pricing pressure:
Government price controls and intense competition in generics can squeeze margins.
OFS structure:
Since the IPO is a 100% OFS, no fresh capital enters the company; proceeds go to selling shareholders, which some long-term investors may view less favorably.

Actionable takeaway: Use these risks to size the position conservatively and avoid overexposure, especially if applying purely for listing gains.

Should You Apply for the Corona Remedies IPO?

Whether to apply depends on risk appetite, time horizon, and portfolio allocation strategy.

The Corona Remedies IPO may suit:

Investors may find the Corona Remedies IPO appealing if they seek exposure to a mid-sized, branded pharma player with strong ROCE and consistent margins.
Short-term traders aiming for possible listing gains supported by a healthy Corona Remedies IPO GMP and positive sentiment.

It may not suit:

Ultra-conservative investors who have a preference for large-cap, low-volatility stocks may not find this approach suitable.
Investors are uncomfortable with OFS-only structures where no new funds are infused in the company.

A disciplined approach is to cap allocation per IPO (for example, 5–10% of your equity portfolio in total IPO exposure) and diversify across sectors.

How to Apply for Corona Remedies IPO Online

Applying online is straightforward through most discount and full-service brokers.

Basic steps for applying:

Log in to your broker’s app or net-banking portal that supports ASBA.
Search for Corona Remedies IPO and select the issue.
Choose the investor category (Retail/HNI), select the cut-off price for simplicity, and enter the number of lots.
Please confirm the UPI mandate or ASBA block request in your bank app.

For a practical walk-through, refer to your broker’s IPO help section or NSE/BSE investor education pages.

Actionable IPO Investing Tips for Readers

To keep readers engaged and encourage long page visits, include clear, practical advice they can immediately apply:

Always read the RHP (Red Herring Prospectus) and check the revenue mix, top products, and dependency on a few brands.
Compare Corona Remedies’ margins, ROCE, and valuation multiples with listed mid-cap pharma peers before subscribing.
Avoid applying for every IPO; build a watchlist and prioritize those with strong fundamentals plus reasonable valuations.
After the IPO listing, investors should establish a clear exit or holding strategy, such as booking partial profits on significant gains while retaining the remaining shares if the company’s fundamentals remain strong.

Internal and External Links

Within your site, you can internally link this article to:

A detailed guide on “How to analyze pharma IPOs using financial ratios”
A step-by-step tutorial: “How to apply for IPOs using UPI and ASBA”
A recent post on another issue, such as “Vidya Wires IPO review” or “Meesho IPO: long-term vs. listing gain strategy”

For an authoritative external source, link to the SEBI or NSE/BSE IPO section where investors can download the official RHP and check live issue data.